The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng./ml.: Relation to biopsy strategy

Journal of Urology

Volumn 165, Issue 3, 2001, Pages 757-760

  Babaian, Richard J ^a,b   Johnston, Dennis A ^a,b   Naccarato, William ^a,b   Ayala, Alberto ^a,b   Bhadkamkar, Vijaya A ^a,b   Fritsche, Herbert A ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b SIEMENS CORPORATE RESEARCH   (United States)

Author keywords

Biopsy; Incidence; Mass screening; Prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SCREENING; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER;

EID: 0035136777     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)66519-6     Document Type: Article

References (15)

1. Prostate specific antigen density: A means of distinguishing benign prostatic hypertrophy and prostate cancer
2. The role of prostate-specific antigen as part of the diagnostic triad and as a guide when to perform a biopsy
3. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges
4. Comparative analysis of prostate specific antigen and its indexes in the detection of prostate cancer
5. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements
6. Prostate cancer detection at low prostate specific antigen
7. Prostate-specific antigen levels in 1695 men without evidence of prostate cancer. Findings of the American Cancer Society National Prostate Cancer Detection Project
8. Cancer control and quality of life following anatomical radical retropubic prostatectomy: Results at 10 years
9. A comparative analysis of sextant and extended 11-core multisite directed biopsy strategy
10. Tumor volume and prostate specific antigen: Implications for early detection and defining a window of curability
11. Detection of clinically significant prostate cancer by transrectal ultrasound-guided systematic biopsies
12. European randomized study of screening for prostate cancer - The Rotterdam pilot studies
13. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer
14. Radiation therapy for T1 and T2 prostate cancer: Prostate-specific antigen and disease outcome
15. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years